Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Mediclinic International Plc
  6. News
  7. Summary
    MDC   GB00B8HX8Z88


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Mediclinic International plc Announces Directorate Change

07/27/2021 | 09:00am EDT

Mediclinic announced the appointment of two new independent non-executive directors: Natalia Barsegiyan and Zarina Bassa. Natalia Barsegiyan is currently a non-executive director of Domino's Pizza Group plc, the FTSE 250 digitally-enabled, quick service international restaurant group and is a member of their Audit Committee. She also acts as an adviser to Kharis Capital, a private equity firm based in Belgium. Prior to this, the majority of Natalia's career was with the US group Yum! Brands Inc., owner of a portfolio of many well-known brands such as KFC, Pizza Hut and Taco Bell, where she served as Chief Commercial Officer of the Group and then Chief Financial Officer of Taco Bell. Her appointment as a director of Mediclinic will become effective on 1 August 2021. Natalia will bring a strong finance background with a commercial and strategic focus, an in-depth understanding of the use of data analytics to support transformation and broad international experience, having lived and worked across the US, Europe, Russia and the UK. Zarina Bassa is currently the senior independent director of Investec plc and Investec Ltd, the specialist banking and wealth management group with a dual listed company structure and listings on the London and Johannesburg Stock Exchanges; lead independent director of Woolworths Holdings Ltd; and non-executive director of JSE Ltd. and Oceana Group Ltd. (the last three all being South African companies with a listing on the Johannesburg Stock Exchange). Zarina has stepped down as Chair of Yebo Yethu Ltd. and previously served as a non-executive director at several other companies including Kumba Iron Ore Ltd; Mercedes Benz SA Ltd; Sun International Ltd; Vodacom South Africa Proprietary Limited; the South African Institute of Chartered Accountants; and the Financial Services Board. Prior to that, she was a partner of Ernst & Young Inc. and then joined the Absa Group in 2002, where she served as an executive director of Absa Bank, a member of the group's executive committee, and Head of the Private Bank. Zarina's appointment as a director of Mediclinic will become effective on 1 February 2022. The Board of Mediclinic has carefully considered Zarina's existing time commitments and is satisfied that she will have sufficient time to dedicate to fulfil her responsibilities to the Group. She will contribute strategic and operational experience in complex, regulated environments, a strong financial and accounting background, and diverse experience in listed companies across a breadth of sectors and jurisdictions. Following a review of the Board Committee structure and responsibilities, the Board has decided to separate the responsibilities of the Clinical Performance and Sustainability Committee, to allow for more time to dedicate to the oversight of these key aspects of the Group's strategy and operations. Accordingly, with effect from 1 September 2021: the Clinical Performance and Sustainability Committee will become a focused Clinical Performance Committee. There will be no change in its composition; and a new Environmental, Social and Governance Committee will be established, chaired by Dame Inga, with other members comprising: Dr. Ronnie van der Merwe, Natalia Barsegiyan, Dr. Felicity Harvey and Danie Meintjes. Natalia Barsegiyan will also join the Audit and Risk Committee upon her appointment as a non-executive director; Zarina Bassa will join the Audit and Risk and Remuneration Committees when her appointment as non-executive director becomes effective; Dr Muhadditha Al Hashimi will join the Remuneration Committee on 13 September 2021; and Tom Singer will join the Investment Committee on 13 September 2021.

© S&P Capital IQ 2021
09/03Mediclinic to procure renewable energy in a $152 million deal
09/03MEDICLINIC INTERNATIONAL : To Source Green Electricity From South Africa's Energ..
07/28Mediclinic International plc Appoints Zarina Bassa as Non-Executive Director,..
07/27Mediclinic International plc Announces Directorate Change
07/27FTSE Falls as Miners, Banks and Reckitt Drop
07/27MEDICLINIC INTERNATIONAL : Still Expects FY22 Earnings Growth Amid Pandemic
06/18MEDICLINIC INTERNATIONAL PLC : Mixed general shareholder meeting
06/14MEDICLINIC INTERNATIONAL PLC : Crossing thresholds
05/26Australia's Ramsay Health Care to buy UK's Spire for $1.4 billion
05/26Mediclinic to Receive $407 Million for Spire Healthcare Stake Amid Acquisitio..
More news
More recommendations
Sales 2022 3 084 M 4 236 M 4 236 M
Net income 2022 150 M 206 M 206 M
Net Debt 2022 1 870 M 2 569 M 2 569 M
P/E ratio 2022 16,1x
Yield 2022 1,21%
Capitalization 2 353 M 3 237 M 3 233 M
EV / Sales 2022 1,37x
EV / Sales 2023 1,30x
Nbr of Employees 30 470
Free-Float 55,3%
Duration : Period :
Mediclinic International Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDICLINIC INTERNATIONAL PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 319,20 GBX
Average target price 347,78 GBX
Spread / Average Target 8,95%
EPS Revisions
Managers and Directors
C. A. Ronnie van der Merwe Chief Executive Officer & Executive Director
Petrus Jurgens Myburgh Chief Financial Officer & Executive Director
Inga Kristine Beale Non Executive Chairman
Dirk Le Roux Chief Information Officer
Rene Toua Chief Clinical Officer
Sector and Competitors